B4GALT4

Across TCGA pan-cancer cohorts, B4GALT4 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated B4GALT4 data layer compared with 24 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher B4GALT4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated B4GALT4 expression acts as an unfavorable survival marker, although some lineages such as STAD and UCEC show a favorable association.

BRCA, READ, and LUSC are the cancer types where B4GALT4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	III,IV	0.233	0.833	<.001	14	view →
READ	OS	Median	All	0.183	0.828	<.001	12	view →
LUSC	OS	Median	All	0.011	0.819	<.001	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
STAD	DFS	Median	III,IV	1.000	0.337	.031	6	view →
UCEC	DFS	Median	All	0.942	0.629	.045	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

B4GALT4–BRCA (OS)

Open the BRCA breakdown →